Results 211 to 220 of about 26,895 (263)

mTOR blockade prevents progressive proteinuria but induces hyperglycaemia in obese Dahl salt‐sensitive rats before puberty

Experimental Physiology, EarlyView.
Abstract Previous studies have demonstrated that mammalian target of rapamycin (mTOR) activity is significantly increased in the kidneys of Dahl salt‐sensitive (SS) rats during the development of renal injury. Therefore, in the present study we examined whether blockade of mTOR with rapamycin inhibits renal injury in Dahl salt‐sensitive leptin receptor
Sautan Mandal, Andrea K. Brown, Ubong S. Ekperikpe, Anukool A. Bhopatkar, Krystle M. Hughes, Tyler D. Johnson, Jonita S. Cooper, Konnor T. Wilbert, Denise C. Cornelius, Jan M. Williams   +9 more
wiley   +1 more source

Euglycemic diabetic ketoacidosis with gastrointestinal dysfunction following lung surgery in a patient on SGLT2 inhibitor: a case report. [PDF]

AME Case Rep
Liu Y, Wen J, Cai W, Jin J, Hu M, Han H, Qiu X, Xue Z.   +7 more
europepmc   +1 more source

Sodium–glucose cotransporter 2 inhibitors for hypertension in cardiovascular–kidney–metabolic syndrome

Experimental Physiology, EarlyView.
Abstract The antihypertensive mechanism of sodium–glucose cotransporter 2 (SGLT2) inhibitors has been traditionally attributed to osmotic diuresis. However, emerging evidence reveals multifaceted mechanisms beyond diuresis, including regulation of the renin–angiotensin–aldosterone system, sympathetic nervous system suppression, ion homeostasis ...
Chunxiang Xu, Xingyu Qiu, Nan Xu, Gensheng Zhang, Enyin Lai, Liang Zhao   +5 more
wiley   +1 more source

Dietary interventions in acute kidney injury: From molecular mechanism to clinical trials

Experimental Physiology, EarlyView.
Abstract Ageing impairs renal resilience with an elevated risk of frequent and harmful acute kidney injury (AKI) that causes substantial morbidity and mortality among hospitalized patients. Since different damaging stimuli at the molecular, cellular and functional level contribute to this loss in kidney function, AKI's pathophysiology is heterogeneous ...
Felix C. Koehler, Pedro Rojas‐Morales, Roman‐Ulrich Müller   +2 more
wiley   +1 more source

Cardiac remodelling in type 2 diabetes: Pathophysiological mechanisms and opportunities for multiscale computational modelling and simulation

The Journal of Physiology, EarlyView.
Abstract figure legend Overview of multiscale cardiac remodelling in type 2 diabetes and how to model and simulate these changes using a human‐based, multiscale computational framework. Cardiac remodelling in type 2 diabetes occurs at ionic channel, protein, cellular, tissue and whole‐organ level, affecting the electrophysiological function, mechanical
Ambre Bertrand, Jakub Tomek, Blanca Rodriguez   +2 more
wiley   +1 more source

Cardiorenal Outcomes of Dapagliflozin vs. Empagliflozin in Advanced Chronic Kidney Disease and Diabetes

Clinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 168-177, July 2026.
Target trial emulation of a multi‐institutional electronic health record network showed comparable cardiorenal effectiveness and safety of dapagliflozin versus empagliflozin in adults with type 2 diabetes and advanced‐stage chronic kidney disease.
Shih‐Hsuan Lin, Jia‐Jin Chen, Ching‐Chung Hsiao, Yu‐Wei Fang, Meng‐Ting Chen, Ming‐Hsien Tsai, Huang‐Yu Yang   +6 more
wiley   +1 more source

Efficacy and safety of switching to iGlarLixi from premixed insulin therapy in patients with type 2 diabetes: A real‐world experience

Diabetic Medicine, Volume 43, Issue 7, July 2026.
Abstract Aims Fixed‐ratio combinations such as iGlarLixi are recommended over premixed insulin as first‐line injectable therapy for type 2 diabetes mellitus (T2DM), yet real‐world evidence on transitions from premix to iGlarLixi remains limited. This study aimed to evaluate the efficacy and safety of switching from premixed insulin to iGlarLixi in a ...
Chun‐Jui Huang, Shun‐Jie Yang, Cheng‐Pin Cheng, Chun‐Hsing Lin, Ya‐Chun Lee, Harn‐Shen Chen   +5 more
wiley   +1 more source

A systematic review and meta‐analysis of the relative benefit of dual versus single oral hypoglycaemic therapy following diagnosis with type 2 diabetes (T2D)

Diabetic Medicine, Volume 43, Issue 7, July 2026.
Abstract Introduction Achieving and sustaining target glycated haemoglobin (HbA1c) levels is fundamental in the management of type 2 diabetes (T2D). We here aimed to assess whether initial dual oral therapy outperforms monotherapy in reaching glycaemic targets in patients with treatment‐naive or early‐stage T2D.
Mairead Kelly, Sushant Saluja, Hugh Logan Ellis, Sarah Jamil, Martin B. Whyte, Adrian Heald   +5 more
wiley   +1 more source

Short-Term Laboratory Outcomes of SGLT2 Inhibitor Use in Type 2 Diabetic Patients: A Retrospective Analysis. [PDF]

J Clin Med
AlSudais H, AlSulaiman T, Alotaibi BA, Alshalani A, Almuqrin AM, Albakr RB, Aldali JA.   +6 more
europepmc   +1 more source

Patterns in Prescribing and Predictors of SGLT2 Inhibitor Administration in Patients with Heart Failure and Acute Myocardial Infarction: A Real-World Retrospective Cohort Study. [PDF]

J Clin Med
Suciu IM, Mateoc-Sîrb T, Luca CT, Timar B, Gaiță D.   +4 more
europepmc   +1 more source